The part that is most intriguing to me is the part that sounded like the auxiliary group performed outstanding with clear efficacy.
Because the obvious purpose of that arm is to make sure nobody is cheating.
So by the sounds of things, if that's right, then we should be good to go, new doors to open with this tech, and maybe only a $7B/yr concern, but that's not too bad, for now.
Making a dent in this cancer thing is a big deal.
I have little reason to believe with what they've said that we can expect the over all test/control comparison to come up to what they've said about the sub-group.
Just remember though we can make it on secondary measures alone, and there is reason to believe that is going to be good.
The data, so far, also seems to suggest the theory is correct, put immunotherapy before Chemo ( if not eliminate chemo altogether )
Mustard Gas can't be good
Why not just use chlorine
Market Data 
Markets 
AI
